Ligand-based virtual screen for the discovery of novel M5 inhibitor chemotypes

Bioorg Med Chem Lett. 2016 Sep 15;26(18):4487-4491. doi: 10.1016/j.bmcl.2016.07.071. Epub 2016 Jul 30.

Abstract

This Letter describes a ligand-based virtual screening campaign utilizing SAR data around the M5 NAMs, ML375 and VU6000181. Both QSAR and shape scores were employed to virtually screen a 98,000-member compound library. Neither approach alone proved productive, but a consensus score of the two models identified a novel scaffold which proved to be a modestly selective, but weak inhibitor (VU0549108) of the M5 mAChR (M5 IC50=6.2μM, M1-4 IC50s>10μM) based on an unusual 8-((1,3,5-trimethyl-1H-pyrazol-4-yl)sulfonyl)-1-oxa-4-thia-8-azaspiro[4,5]decane scaffold. [(3)H]-NMS binding studies showed that VU0549108 interacts with the orthosteric site (Ki of 2.7μM), but it is not clear if this is negative cooperativity or orthosteric binding. Interestingly, analogs synthesized around VU0549108 proved weak, and SAR was very steep. However, this campaign validated the approach and warranted further expansion to identify additional novel chemotypes.

Keywords: M(5); Muscarinic acetylcholine receptor; Structure–activity relationship (SAR); Virtual screen.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • CHO Cells
  • Cricetulus
  • Drug Discovery
  • Humans
  • Ligands
  • Muscarinic Antagonists / chemistry
  • Muscarinic Antagonists / pharmacology
  • Quantitative Structure-Activity Relationship
  • Receptor, Muscarinic M5 / antagonists & inhibitors*

Substances

  • Ligands
  • Muscarinic Antagonists
  • Receptor, Muscarinic M5